Immunotherapy Coverage from Every Angle

Recent News

Early-Stage Clinical Study of Novel BCMA CAR T-Cell Therapy in Resistant Myeloma
Does Combination Immunotherapy Improve Survival in Metastatic Uveal Melanoma?
Adding Palbociclib to Cetuximab in Platinum-Resistant Head and Neck Cancer
FOLFOXIRI Plus Bevacizumab in Unresectable Coloretcal Cancer: Update From TRIBE2
CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL
Epacadostat With Pembrolizumab in Advanced Melanoma
IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer
Novel Monoclonal Antibody Plus Cetuximab Under Study in Head/Neck Cancer
Infliximab Therapy With Tyrosine Kinase Inhibition in CML
Nivolumab for Advanced Renal Cell Carcinoma: 5-Year Survival
Using Immuno-PET to Detect PD-L1 in Renal Cell Carcinoma: Case Report
CD19-Directed Immunotherapy for Relapsed or Refractory CLL
Bempegaldesleukin With Nivolumab Granted Breakthrough Therapy Designation in Melanoma
FDA Approves Rituximab Biosimilar for CLL
FDA Approves Pembrolizumab in PD-L1–Expressing Squamous Cell Carcinoma of the Esophagus
Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma
Does Eribulin Mesylate Plus Pembrolizumab Improve Outcomes in Metastatic Breast Cancer?
Checkpoint Inhibitors in Oropharyngeal Cancer: Window-of-Opportunity Trial
Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer
Intermittent Nivolumab Dosing for Metastatic Renal Cell Carcinoma
First Clinical Immunotherapy Treatment Guidelines for Squamous Cell Carcinoma of the Head and Neck
Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma
Novel Immunotherapy Combination Active in Metastatic Melanoma
FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Merkel Cell Carcinoma
FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Melanoma
Cemiplimab-rwlc Approved for Advanced Cutaneous Squamous Cell Carcinoma in European Union
Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?
EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma
SOPHIA Trial: Adding Margetuximab or Trastuzumab to Chemotherapy in Breast Cancer
EAGLE Trial: Novel Immunotherapies for Resistant Head/Neck Cancer
Atezolizumab Plus Bevacizumab for Sarcomatoid Metastatic Renal Cell Carcinoma
Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma
ICML 2019: Improved Outcomes With Brentuximab Vedotin in Cutaneous Lymphoma
FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC
ICML 2019: Mogamulizumab in Cutaneous T-Cell Lymphoma
FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.